Etiology, Pathophysiology, and Treatment Strategies in the Prevention and Management of Metabolic Syndrome - PubMed

Etiology, Pathophysiology, and Treatment Strategies in the Prevention and Management of Metabolic Syndrome

Ritika Patial et al. Arch Intern Med Res. 2024.

Abstract

Metabolic Syndrome (MetS) is a complex cluster of metabolic irregularities that significantly increase the risk of developing chronic conditions, such as hypertension, type 2 diabetes, cardiovascular diseases, and other related disorders. This review aims to provide a comprehensive overview of the current understanding of MetS, its etiology and underlying pathogenesis, and the management strategies. MetS is characterized by central obesity, high blood pressure, insulin resistance, hyperglycemia, hypertriglyceridemia, and low high-density lipoprotein cholesterol levels. The prevalence of MetS is remarkably high, affecting approximately 25% of the global population, particularly in developed nations with inactive lifestyles and high-calorie diets. The development of MetS involves genetic and acquired factors, resulting in an inflammatory state that enhances the risk for cardiovascular disease. The biochemical alterations observed in MetS establish pathological connections between MetS, diabetes, and cardiovascular and neurodegenerative conditions. Despite its clinical importance, there is still debate regarding the precise components and pathophysiological associations among MetS elements. However, advancements in therapeutic measures, including drug therapies, surgical options, and experimental methods present promising avenues for managing and potentially reversing MetS. Further investigation of the MetS is critical because of its significant implications for public health and its connection to other clinical conditions and severe health outcomes, placing a substantial burden on healthcare system and society.

Keywords: Cardiovascular diseases; Inflammation; Insulin resistance; Lipid metabolism; Metabolic Syndrome; Obesity; Type 2 diabetes.

Conflict of interest statement

Conflicts of Interest: The authors declare no conflict of interest

Figures

Similar articles

• Effects of Microalgae on Metabolic Syndrome.

  Tamel Selvan K, Goon JA, Makpol S, Tan JK. Tamel Selvan K, et al. Antioxidants (Basel). 2023 Feb 10;12(2):449. doi: 10.3390/antiox12020449. Antioxidants (Basel). 2023. PMID: 36830009 Free PMC article. Review.

• Targeting inflammation in metabolic syndrome.

  Welty FK, Alfaddagh A, Elajami TK. Welty FK, et al. Transl Res. 2016 Jan;167(1):257-80. doi: 10.1016/j.trsl.2015.06.017. Epub 2015 Jul 3. Transl Res. 2016. PMID: 26207884 Free PMC article. Review.

• The association between metabolic syndrome components, low-grade systemic inflammation and insulin resistance in non-diabetic Indonesian adolescent male.

  Mansyur MA, Bakri S, Patellongi IJ, Rahman IA. Mansyur MA, et al. Clin Nutr ESPEN. 2020 Feb;35:69-74. doi: 10.1016/j.clnesp.2019.12.001. Epub 2020 Jan 1. Clin Nutr ESPEN. 2020. PMID: 31987123

• Adipokines demonstrate the interacting influence of central obesity with other cardiometabolic risk factors of metabolic syndrome in Hong Kong Chinese adults.

  Supriya R, Tam BT, Yu AP, Lee PH, Lai CW, Cheng KK, Yau SY, Chan LW, Yung BY, Sheridan S, Siu PM. Supriya R, et al. PLoS One. 2018 Aug 16;13(8):e0201585. doi: 10.1371/journal.pone.0201585. eCollection 2018. PLoS One. 2018. PMID: 30114249 Free PMC article.

• Carbohydrate restriction improves the features of Metabolic Syndrome. Metabolic Syndrome may be defined by the response to carbohydrate restriction.

  Volek JS, Feinman RD. Volek JS, et al. Nutr Metab (Lond). 2005 Nov 16;2:31. doi: 10.1186/1743-7075-2-31. Nutr Metab (Lond). 2005. PMID: 16288655 Free PMC article.

References